| Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial P Tebas, SP Yang, JD Boyer, EL Reuschel, A Patel, A Christensen-Quick, ... EClinicalMedicine 31, 2021 | 242 | 2021 |
| Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at … MP Mammen Jr, P Tebas, J Agnes, M Giffear, KA Kraynyak, E Blackwood, ... medRxiv, 2021.05. 07.21256652, 2021 | 51 | 2021 |
| SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial KA Kraynyak, E Blackwood, J Agnes, P Tebas, M Giffear, D Amante, ... The Journal of infectious diseases 225 (11), 1923-1932, 2022 | 40 | 2022 |
| Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes SS Soldan, C Su, RJ Lamontagne, N Grams, F Lu, Y Zhang, JD Gesualdi, ... PLoS Pathogens 17 (6), e1009618, 2021 | 26 | 2021 |
| EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer SS Soldan, EM Anderson, DM Frase, Y Zhang, LB Caruso, Y Wang, ... Gastric Cancer 24 (5), 1076-1088, 2021 | 23 | 2021 |
| Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021; 31: 100689 P Tebas, S Yang, JD Boyer, EL Reuschel, A Patel, A Christensen-Quick, ... J. ECLINM, 2020 | 18 | 2020 |
| Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection KM Konrath, K Liaw, Y Wu, X Zhu, SN Walker, Z Xu, K Schultheis, ... Cell reports 38 (5), 2022 | 17 | 2022 |
| DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2 EM Parzych, J Du, AR Ali, K Schultheis, D Frase, TRF Smith, J Cui, ... Nature Communications 13 (1), 5886, 2022 | 16 | 2022 |
| Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates JN Walters, B Schouest, A Patel, EL Reuschel, K Schultheis, E Parzych, ... Vaccine 40 (21), 2960-2969, 2022 | 12 | 2022 |
| Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism A Calderon, SS Soldan, A De Leo, Z Deng, DM Frase, EM Anderson, ... Oncotarget 11 (46), 4224, 2020 | 12 | 2020 |
| Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo EN Gary, NJ Tursi, B Warner, EM Parzych, AR Ali, D Frase, E Moffat, ... Cell Reports Medicine 3 (7), 2022 | 11 | 2022 |
| The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis D Frase, C Lee, C Nachiappan, R Gupta, A Akkouch Cells 12 (13), 1744, 2023 | 6 | 2023 |
| Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge EN Gary, NJ Tursi, BM Warner, G Cuismano, J Connors, EM Parzych, ... Frontiers in Immunology 14, 1138609, 2023 | 4 | 2023 |
| Does stream current modify crayfish impacts on a benthic community? T Wellnitz, D Frase, M Gapinski, HE Haggerty Journal of Freshwater Ecology 34 (1), 633-647, 2019 | 3 | 2019 |
| 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster P Tebas, J Agnes, M Giffear, KA Kraynyak, E Blackwood, D Amante, ... Open Forum Infectious Diseases 8 (Supplement_1), S387-S388, 2021 | 1 | 2021 |
| In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates A Patel, K Rosenke, EM Parzych, F Feldmann, S Bharti, AJ Griffin, ... Emerging Microbes & Infections 13 (1), 2294860, 2024 | | 2024 |
| Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge G Cusimano, EN Gary, NJ Tursi, BM Warner, J Connors, EM Parzych, ... The Journal of Immunology 210 (1_Supplement), 252.04-252.04, 2023 | | 2023 |
| Mucosal chemokine adjuvant supports heterologous protection against Delta and Omicron VOCs in the context of a SARS-CoV-2 wild-type DNA vaccine EN Gary, NJ Tursi, BM Warner, EM Parzych, AR Ali, D Frase, E Moffat, ... The Journal of Immunology 210 (1_Supplement), 253.15-253.15, 2023 | | 2023 |
| DNA Delivery of Immune-Focused Nanoparticle Vaccines Drives Rapid, Potent, and Broad Immunogenicity Against Sars-Cov-2 and Its Variants K Liaw, K Konrath, Y Wu, X Xu, S Walker, Z Xu, N Chokkalingam, N Tursi, ... 2022 AIChE Annual Meeting, 2022 | | 2022 |
| Personalized ovarian cancer therapy using in vivo assembled bi-specific antibodies targeting Her2 and FSHR PS Bhojnagarwala, AR Ali, D Frase, A Kulkarni, D Bordoloi, DB Weiner Cancer Research 82 (12_Supplement), 2913-2913, 2022 | | 2022 |
